Literature DB >> 15150345

Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation.

Renaud Snanoudj1, Antoine Durrbach, Eric Gauthier, David Adams, Didier Samuel, Sophie Ferlicot, Pierre Bedossa, Alain Prigent, Henri Bismuth, Bernard Charpentier.   

Abstract

BACKGROUND: Familial amyloid polyneuropathy (FAP) is an autosomal dominant disease caused by a point mutation in the gene encoding transthyretin, which is secreted by the liver. Orthotopic liver transplantation (OLT) has been proposed to prevent disease progression. Little is known about long-term changes in renal function and lesions after OLT.
METHODS: The renal function of 33 patients with FAP was evaluated (proteinuria, serum creatinine, creatinine clearance) before OLT and over a period of at least 5 years afterwards. A pre-transplantation renal biopsy was performed in 14 patients and a follow-up biopsy in eight patients.
RESULTS: Before transplantation, mean serum creatinine concentration was 86 micromol/l (47-126 micromol/l) and creatinine clearance was 71.9+/-31.6 ml/min/1.73 m(2). Proteinuria was detected in 54% of patients (0.3-4 g/day). Pre-transplant renal biopsies (n = 14) revealed glomerular, tubular and vascular amyloid deposits in 90, 58 and 66% of patients, respectively. Eleven patients (33%) died after OLT. Death occurred most frequently in patients having weight losses >7 kg (P<0.05). After transplantation, 25 patients (76%) suffered acute renal failure but only one required dialysis. One month after transplantation, the mean serum creatinine concentration was 134.1+/-73 micromol/l and remained constant during follow-up. Eight patients underwent a second renal biopsy 2 years after transplantation. No significant changes in deposits or renal toxicity due to calcineurin inhibitors were detected.
CONCLUSION: Although liver transplantation in FAP does not affect existing renal amyloid deposits, it prevents the progression of renal disease.

Entities:  

Mesh:

Year:  2004        PMID: 15150345     DOI: 10.1093/ndt/gfh063

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation.

Authors:  Yuki Ohya; Sadahisa Okamoto; Masayoshi Tasaki; Mitsuharu Ueda; Hirofumi Jono; Konen Obayashi; Kazuhisa Takeda; Hideaki Okajima; Katsuhiro Asonuma; Ryuhei Hara; Hidenobu Tanihara; Yukio Ando; Yukihiro Inomata
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

Review 2.  Renal dysfunction in chronic liver disease.

Authors:  Andy Slack; Andrew Yeoman; Julia Wendon
Journal:  Crit Care       Date:  2010-03-09       Impact factor: 9.097

Review 3.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

4.  Review of eprodisate for the treatment of renal disease in AA amyloidosis.

Authors:  Adam Rumjon; Thomas Coats; Muhammad M Javaid
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-02-24

5.  Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients.

Authors:  Justine Solignac; Emilien Delmont; Etienne Fortanier; Shahram Attarian; Julien Mancini; Laurent Daniel; Ioana Ion; Jean-Etienne Ricci; Thomas Robert; Gilbert Habib; Olivier Moranne; Noémie Jourde-Chiche
Journal:  Clin Kidney J       Date:  2022-05-05

Review 6.  Renal amyloidosis: a new time for a complete diagnosis.

Authors:  V A Feitosa; P D M M Neves; L B Jorge; I L Noronha; L F Onuchic
Journal:  Braz J Med Biol Res       Date:  2022-10-03       Impact factor: 2.904

Review 7.  Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Yukio Ando; João Melo Beirão; Teresa Coelho; Morie A Gertz; Julian D Gillmore; Philip N Hawkins; Isabelle Lousada; Ole B Suhr; Giampaolo Merlini
Journal:  J Neurol       Date:  2020-01-06       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.